FDA- HFpEF-breakthrough-designation-EMPEROR-preserved FDA- HFpEF-breakthrough-designation-EMPEROR-preserved U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
CHMP recommends new treatment for chronic kidney disease CHMP recommends new treatment for chronic kidney disease The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy